[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628603":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":33,"responsibleParty":132,"collaborators":134,"id":138,"slug":139,"hasResults":140,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":140,"sex":146,"minAge":147,"maxAge":10,"enrollmentInfo":148,"targetDuration":10,"studyType":151,"phases":10,"briefSummary":152,"conditions":153,"keywords":10,"overallStatus":157,"whyStopped":10,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":167},{"fullName":5,"class":6},"Fondazione Italiana Linfomi - ETS","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with DLBCL\u002FHGBL and PMBCL",null,"Patients with previous diagnosis of Diffuse Large B Cell Lymphoma or High-Grade B Cell Lymphoma (DLBCL\u002FHGBL), arising de novo or transformed from a previous indolent histotype (transformed Follicular Lymphoma or transformed Marginal Zone Lymphoma), Primary Mediastinal B Cell Lymphoma (PMBCL) scheduled to received CAR-T cell product according to Agenzia Italiana del Farmaco (AIFA) indications and technical data sheet of the drug",[13],"Other: Chimeric Antigen Receptor T-cells (CAR-T) therapy",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Chimeric Antigen Receptor T-cells (CAR-T) therapy","Patients will be treated with CAR-T cell product as per routine clinical practice.",[9],[20],{"name":21,"affiliation":22,"role":23},"Luca Castagna","A.O. Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Uffici Studi FIL","CONTACT","+390131033153","startup@filinf.it",{"name":26,"role":27,"phone":31,"phoneExt":10,"email":32},"+39 059 976 9911","gestionestudi@filinf.it",[34,49,61,73,84,96,108,120],{"facility":35,"status":10,"city":36,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"SCDU Ematologia - AOU SS. Antonio e Biagio e Cesare Arrigo di Alessandria","Alessandria","Italy","IT",{"type":40,"coordinates":41},"Point",[42,43],8.61007,44.90924,{"lat":43,"lon":42},[46],{"name":47,"role":27,"phone":10,"phoneExt":10,"email":48},"Manuela Zanni","manuela.zanni@ospedale.al.it",{"facility":50,"status":10,"city":51,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"Clinica di Ematologia, AOU Ospedali Riuniti","Ancona",{"type":40,"coordinates":53},[54,55],13.5103,43.60717,{"lat":55,"lon":54},[58],{"name":59,"role":27,"phone":10,"phoneExt":10,"email":60},"Guido Gini","guido.gini@ospedaliriuniti.marche.it",{"facility":62,"status":10,"city":63,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"USD-TMO Adulti - ASST Spedali Civili di Brescia","Brescia",{"type":40,"coordinates":65},[66,67],10.21472,45.53558,{"lat":67,"lon":66},[70],{"name":71,"role":27,"phone":10,"phoneExt":10,"email":72},"Michele Malagola","michele.malagola@unibs.it",{"facility":74,"status":10,"city":75,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Divisione di Ematologia - A.O. Ospedali Riuniti Villa Sofia-Cervello","Palermo",{"type":40,"coordinates":77},[78,79],13.3636,38.1166,{"lat":79,"lon":78},[82],{"name":21,"role":27,"phone":10,"phoneExt":10,"email":83},"l.castagna@villasofia.it",{"facility":85,"status":10,"city":86,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Ematologia - Grande Ospedale Metropolitano Bianchi Melacrino Morelli","Reggio Calabria",{"type":40,"coordinates":88},[89,90],15.66129,38.11047,{"lat":90,"lon":89},[93],{"name":94,"role":27,"phone":10,"phoneExt":10,"email":95},"Martino Massimo","dr.massimomartino@gmail.com",{"facility":97,"status":10,"city":98,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"Ematologia - Università Cattolica S. Cuore","Roma",{"type":40,"coordinates":100},[101,102],11.10642,44.99364,{"lat":102,"lon":101},[105],{"name":106,"role":27,"phone":10,"phoneExt":10,"email":107},"Simona Sica","simona.sica@unicatt.it",{"facility":109,"status":10,"city":110,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"SC Ematologia - Ospedale \"S.G. Moscati\"","Taranto",{"type":40,"coordinates":112},[113,114],17.24707,40.46438,{"lat":114,"lon":113},[117],{"name":118,"role":27,"phone":10,"phoneExt":10,"email":119},"Claudia Ingrosso","claudia.ingrosso@asl.taranto.it",{"facility":121,"status":10,"city":122,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"SOC Clinica Ematologica - Azienda Sanitaria Universitaria Friuli Centrale (ASU FC)","Udine",{"type":40,"coordinates":124},[125,126],13.23715,46.0693,{"lat":126,"lon":125},[129],{"name":130,"role":27,"phone":10,"phoneExt":10,"email":131},"Jacopo Olivieri","jacopo.olivieri@asufc.sanita.fvg.it",{"type":133,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[135],{"name":136,"class":137},"Fondazione Lorenzo Farinelli Onlus","UNKNOWN","100628603","neurocognitive-assessment-in-adults-undergoing-cd19-targeted-car-t-cell-therapy-100628603",false,"NCT07463781","Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy","Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy: a Multicenter Observational Prospective Study","NEURO_CAR-T","Inclusion Criteria:\n\n* Patients with previous diagnosis of Diffuse Large B Cell Lymphoma or High- Grade B Cell Lymphoma (DLBCL\u002FHGBL), arising de novo or transformed from a previous indolent histotype (transformed Follicular Lymphoma or transformed Marginal Zone Lymphoma), Primary Mediastinal B Cell Lymphoma (PMBCL).\n* Patients undergoing CD19-targeted CAR-T cell salvage therapy for relapsed\u002Frefractory disease according to AIFA inclusion criteria.\n* Age over 18-years-old at the time of lymphoma diagnosis.\n\nExclusion Criteria:\n\n* Patient with histological diagnosis of mantle cell lymphoma (MCL) or acute lymphoblastic leukemia (ALL)\n* Patients with CNS disease localization.\n* Patients that received brain\u002Fneuroaxis radiotherapy.\n* Pre-existing severe psychiatric or neurologic comorbidities influencing neurocognitive assessment.","ALL","18 Years",{"count":149,"type":150},100,"ESTIMATED","OBSERVATIONAL","This is an observational, multicenter, prospective cohort study including patients treated with CAR-T in Italian centers. Patients eligible for enrollment in the study will be consecutively included in Italian FIL centers. A longitudinal survey will be carried out by collecting patients' data before starting CAR-T (T0) and after 6 (T1), 12 (T2) and 24 (T3) months after CAR-T infusion.",[154,155,156],"Diffuse Large B Cell Lymphoma (DLBCL)","High Grade B Cell Lymphoma","Primary Mediastinal B-cell Lymphoma (PMBCL)","NOT_YET_RECRUITING","2026-03-11",{"date":160,"type":161},"2026-03-13","ACTUAL",{"date":163,"type":150},"2026-05",{"date":165,"type":150},"2029-05",{"name":5,"class":6},8]